Centralized and point-of-care division sales contributed most to the revenue growth, and were spurred on by a 13 percent lift in immunodiagnostics revenues.
Myriad said it will submit a supplementary premarket approval application for its BRACAnalysis CDx, which the FDA originally approved in 2014.
The company, which beat Wall Street expectations on the top and bottom lines, said completed Cologuard test volume rose 150 percent over Q1 2016.
The company's second quarter revenue growth was driven in part by strong sales from its life science segment.
Fulgent reached an agreement with two Chinese firms to establish a joint venture to offer genetic testing services in China.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.